Caplyta (lumateperone) has scored a label extension into the depression setting, underscoring the belief Johnson & Johnson (J ...

Cencora is set to invest $1bn by 2030 to expand its US pharmaceutical distribution network, adding resilience and capacity.

Novo Nordisk’s oral therapy Wegovy (semaglutide) reduced cardiovascular risk factors in the Phase III OASIS 4 trial. Being ...

The US Food and Drug Administration (FDA) has approved Linzess (linaclotide) as the first treatment for children living with ...

Leukogene Therapeutics has received orphan drug designation from the US FDA for M2T-CD33 (LTI-214), its immunotherapy candidate targeting AML.